A bill to amend title XI of the Social Security Act to require pharmaceutical and device manufacturers to publicly disclose covered payments made to patient advocacy organizations.

Bill 118 s 5510, also known as the Patient Advocacy Transparency Act, aims to amend title XI of the Social Security Act. The main purpose of this bill is to require pharmaceutical and device manufacturers to publicly disclose any covered payments they make to patient advocacy organizations.

Under this proposed legislation, pharmaceutical and device manufacturers would be required to disclose any payments they make to patient advocacy organizations. This transparency is intended to provide greater insight into the financial relationships between these manufacturers and patient advocacy groups.

By requiring public disclosure of these payments, the bill seeks to promote transparency and accountability in the healthcare industry. This information could help to identify any potential conflicts of interest that may arise from financial relationships between manufacturers and patient advocacy organizations. Overall, the Patient Advocacy Transparency Act aims to increase transparency in the healthcare industry by requiring pharmaceutical and device manufacturers to publicly disclose any covered payments made to patient advocacy organizations. This information could help to ensure that patients and advocacy groups are aware of any financial relationships that may influence healthcare decisions.